European Union - English - EMA (European Medicines Agency)

bayer ag  - vardenafil - erectile dysfunction - urologicals - treatment of erectile dysfunction in adult men.erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.in order for levitra to be effective, sexual stimulation is required.levitra is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 23.705 mg (equivalent: vardenafil, qty 20 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 11.852 mg (equivalent: vardenafil, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 5.926 mg (equivalent: vardenafil, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride 5 mg - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil 2.5 mg - levitra® is indicated for the treatment of erectile dysfunction. administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including levitra, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of levitra for the safe administration of nitrates or nitric oxide donors has not been determined. do not use levitra in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including levitra may potentiate the hypotensive effects of gc stimulators. levitra is not indicated for use in women. there are no studies of levitra use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. th

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil 20 mg - levitra ® is indicated for the treatment of erectile dysfunction. administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology ( 12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including levitra, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of levitra for the safe administration of nitrates or nitric oxide donors has not been determined. do not use levitra in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including levitra may potentiate the hypotensive effects of gc stimulators. levitra is not indicated for use in women. there are no studies of levitra use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that recei

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride trihydrate 20 mg - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride 5 mg - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.